Loading…

Intravenous immunoglobulin: Revisited - My experience

Background: Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises. Method: Over the last 15 years of my practice I have used IVIg in various severe or recalcitra...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of dermatology 2021-05, Vol.66 (3), p.329-329
Main Authors: Vaishampayan, Sanjeev, Bhati, Surendra, Lachhiramani, Radha, Shrivastava, Shivank, Jain, Prateek, Raghuwanshi, Ajay
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c601n-f34b406815df5422aa88495fc2fef662f3187f54fc3daf128de79beac47e84323
container_end_page 329
container_issue 3
container_start_page 329
container_title Indian journal of dermatology
container_volume 66
creator Vaishampayan, Sanjeev
Bhati, Surendra
Lachhiramani, Radha
Shrivastava, Shivank
Jain, Prateek
Raghuwanshi, Ajay
description Background: Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises. Method: Over the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease,connective tissue disorders , chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities. Result: IVIg a sterile, highly purified preparation containing more than 95% unmodified IgG,was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however , one has to be prepared for anaphylactic reaction which is a theoretical possibility. Conclusion: It can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.
doi_str_mv 10.4103/ijd.IJD_559_17
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d0f998be68f34d90a8c155357630c24b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669123576</galeid><doaj_id>oai_doaj_org_article_d0f998be68f34d90a8c155357630c24b</doaj_id><sourcerecordid>A669123576</sourcerecordid><originalsourceid>FETCH-LOGICAL-c601n-f34b406815df5422aa88495fc2fef662f3187f54fc3daf128de79beac47e84323</originalsourceid><addsrcrecordid>eNp9ks9v0zAUxy0EYqVw5YgiceGSYsc_EnNATGNA0RASgrPlOM_BXWIXJ2nZfz933caKBvLBkv3xx-89fRF6TvCCEUxfu1WzWH5-rziXipQP0IxIWeVUEPIQzTAmMueEsyP0ZBhWGDNKKvIYHVHGmJBCzBBf-jHqDfgwDZnr-8mHtgv11Dn_JvsGGze4EZosz75cZPB7DdGBN_AUPbK6G-DZ9T5HPz6cfj_5lJ99_bg8OT7LjcDE55aymmFREd5YzopC66pikltTWLBCFDaVU6Yba2ijLSmqBkpZgzashIrRgs7Rcu9tgl6pdXS9jhcqaKeuDkJslY6jMx2oBtvUeQ2iSr82EuvKEM4pLwXFpmB1cr3du9ZT3UNjYNd4dyA9vPHup2rDRlW0TCKaBK-uBTH8mmAYVe8GA12nPaTpqYILgamQbFf3y7_QVZiiT6NKFKeMcILvUK1ODThvQ_rX7KTqWAhJiqvq5yi_h2rBQyoyeLAuHR_wi3v4tBronfnfAxPDMESwtzMhWO1CplLI1J-QpQcv7k7yFr9JVQLe7YFt6EaIw3k3bSGqxJ77sP2HVtFCqps00kvqY-Fy</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553415102</pqid></control><display><type>article</type><title>Intravenous immunoglobulin: Revisited - My experience</title><source>Publicly Available Content Database</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><creator>Vaishampayan, Sanjeev ; Bhati, Surendra ; Lachhiramani, Radha ; Shrivastava, Shivank ; Jain, Prateek ; Raghuwanshi, Ajay</creator><creatorcontrib>Vaishampayan, Sanjeev ; Bhati, Surendra ; Lachhiramani, Radha ; Shrivastava, Shivank ; Jain, Prateek ; Raghuwanshi, Ajay</creatorcontrib><description>Background: Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises. Method: Over the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease,connective tissue disorders , chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities. Result: IVIg a sterile, highly purified preparation containing more than 95% unmodified IgG,was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however , one has to be prepared for anaphylactic reaction which is a theoretical possibility. Conclusion: It can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.</description><identifier>ISSN: 0019-5154</identifier><identifier>EISSN: 1998-3611</identifier><identifier>DOI: 10.4103/ijd.IJD_559_17</identifier><identifier>PMID: 34446966</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Care and treatment ; chronic dermatoses ; Contraindications ; Immunoglobulins ; Immunotherapy ; indications ; intravenous immunoglobulin-revisited ; Intravenous therapy ; Original ; Skin diseases</subject><ispartof>Indian journal of dermatology, 2021-05, Vol.66 (3), p.329-329</ispartof><rights>Copyright: © 2021 Indian Journal of Dermatology.</rights><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2021 Indian Journal of Dermatology 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c601n-f34b406815df5422aa88495fc2fef662f3187f54fc3daf128de79beac47e84323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375533/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2553415102?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34446966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vaishampayan, Sanjeev</creatorcontrib><creatorcontrib>Bhati, Surendra</creatorcontrib><creatorcontrib>Lachhiramani, Radha</creatorcontrib><creatorcontrib>Shrivastava, Shivank</creatorcontrib><creatorcontrib>Jain, Prateek</creatorcontrib><creatorcontrib>Raghuwanshi, Ajay</creatorcontrib><title>Intravenous immunoglobulin: Revisited - My experience</title><title>Indian journal of dermatology</title><addtitle>Indian J Dermatol</addtitle><description>Background: Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises. Method: Over the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease,connective tissue disorders , chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities. Result: IVIg a sterile, highly purified preparation containing more than 95% unmodified IgG,was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however , one has to be prepared for anaphylactic reaction which is a theoretical possibility. Conclusion: It can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.</description><subject>Care and treatment</subject><subject>chronic dermatoses</subject><subject>Contraindications</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>indications</subject><subject>intravenous immunoglobulin-revisited</subject><subject>Intravenous therapy</subject><subject>Original</subject><subject>Skin diseases</subject><issn>0019-5154</issn><issn>1998-3611</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks9v0zAUxy0EYqVw5YgiceGSYsc_EnNATGNA0RASgrPlOM_BXWIXJ2nZfz933caKBvLBkv3xx-89fRF6TvCCEUxfu1WzWH5-rziXipQP0IxIWeVUEPIQzTAmMueEsyP0ZBhWGDNKKvIYHVHGmJBCzBBf-jHqDfgwDZnr-8mHtgv11Dn_JvsGGze4EZosz75cZPB7DdGBN_AUPbK6G-DZ9T5HPz6cfj_5lJ99_bg8OT7LjcDE55aymmFREd5YzopC66pikltTWLBCFDaVU6Yba2ijLSmqBkpZgzashIrRgs7Rcu9tgl6pdXS9jhcqaKeuDkJslY6jMx2oBtvUeQ2iSr82EuvKEM4pLwXFpmB1cr3du9ZT3UNjYNd4dyA9vPHup2rDRlW0TCKaBK-uBTH8mmAYVe8GA12nPaTpqYILgamQbFf3y7_QVZiiT6NKFKeMcILvUK1ODThvQ_rX7KTqWAhJiqvq5yi_h2rBQyoyeLAuHR_wi3v4tBronfnfAxPDMESwtzMhWO1CplLI1J-QpQcv7k7yFr9JVQLe7YFt6EaIw3k3bSGqxJ77sP2HVtFCqps00kvqY-Fy</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Vaishampayan, Sanjeev</creator><creator>Bhati, Surendra</creator><creator>Lachhiramani, Radha</creator><creator>Shrivastava, Shivank</creator><creator>Jain, Prateek</creator><creator>Raghuwanshi, Ajay</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Wolters Kluwer - Medknow</general><general>Wolters Kluwer Medknow Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210501</creationdate><title>Intravenous immunoglobulin: Revisited - My experience</title><author>Vaishampayan, Sanjeev ; Bhati, Surendra ; Lachhiramani, Radha ; Shrivastava, Shivank ; Jain, Prateek ; Raghuwanshi, Ajay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c601n-f34b406815df5422aa88495fc2fef662f3187f54fc3daf128de79beac47e84323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>chronic dermatoses</topic><topic>Contraindications</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>indications</topic><topic>intravenous immunoglobulin-revisited</topic><topic>Intravenous therapy</topic><topic>Original</topic><topic>Skin diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vaishampayan, Sanjeev</creatorcontrib><creatorcontrib>Bhati, Surendra</creatorcontrib><creatorcontrib>Lachhiramani, Radha</creatorcontrib><creatorcontrib>Shrivastava, Shivank</creatorcontrib><creatorcontrib>Jain, Prateek</creatorcontrib><creatorcontrib>Raghuwanshi, Ajay</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Indian journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vaishampayan, Sanjeev</au><au>Bhati, Surendra</au><au>Lachhiramani, Radha</au><au>Shrivastava, Shivank</au><au>Jain, Prateek</au><au>Raghuwanshi, Ajay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous immunoglobulin: Revisited - My experience</atitle><jtitle>Indian journal of dermatology</jtitle><addtitle>Indian J Dermatol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>66</volume><issue>3</issue><spage>329</spage><epage>329</epage><pages>329-329</pages><issn>0019-5154</issn><eissn>1998-3611</eissn><abstract>Background: Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises. Method: Over the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease,connective tissue disorders , chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities. Result: IVIg a sterile, highly purified preparation containing more than 95% unmodified IgG,was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however , one has to be prepared for anaphylactic reaction which is a theoretical possibility. Conclusion: It can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>34446966</pmid><doi>10.4103/ijd.IJD_559_17</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0019-5154
ispartof Indian journal of dermatology, 2021-05, Vol.66 (3), p.329-329
issn 0019-5154
1998-3611
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d0f998be68f34d90a8c155357630c24b
source Publicly Available Content Database; DOAJ Directory of Open Access Journals; PubMed Central
subjects Care and treatment
chronic dermatoses
Contraindications
Immunoglobulins
Immunotherapy
indications
intravenous immunoglobulin-revisited
Intravenous therapy
Original
Skin diseases
title Intravenous immunoglobulin: Revisited - My experience
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T06%3A12%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20immunoglobulin:%20Revisited%20-%20My%20experience&rft.jtitle=Indian%20journal%20of%20dermatology&rft.au=Vaishampayan,%20Sanjeev&rft.date=2021-05-01&rft.volume=66&rft.issue=3&rft.spage=329&rft.epage=329&rft.pages=329-329&rft.issn=0019-5154&rft.eissn=1998-3611&rft_id=info:doi/10.4103/ijd.IJD_559_17&rft_dat=%3Cgale_doaj_%3EA669123576%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c601n-f34b406815df5422aa88495fc2fef662f3187f54fc3daf128de79beac47e84323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2553415102&rft_id=info:pmid/34446966&rft_galeid=A669123576&rfr_iscdi=true